US EditionSemaglutide More Effective Than Empagliflozin at Lowering Cardiovascular Risks
Summary by Managed Healthcare Executive
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Obesity has become a public health problem, with an economic impact of more than 2% of the world's GDP.Excess weight is also associated with an increased risk of cardiovascular diseases, such as high blood pressure, ischemic heart disease, heart failure or stroke.More information (Auto) Title news (Auto) 117389028Wegovy is the new drug approved by the Spanish Agency for Medicines and Health Products to lose weight.However, a new study has demons…
Semaglutide More Effective Than Empagliflozin at Lowering Cardiovascular Risks
Semaglutide appears to reduce the risk of death, heart attack and stroke in adults with type 2 diabetes more effectively than empagliflozin and dulaglutide, according to a study published in the Annals of Internal Medicine.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
